PredictrPK® IFX Induction
Use
The PredictrPK IFX Induction test is designed to optimize infliximab dosing in IBD patients by predicting IFX levels at 4, 6, and 8 weeks post-induction dose 3. It calculates infliximab clearance and measures serum infliximab, antibodies-to-infliximab (ATI), and albumin levels. This enables more precise dose escalation and aids in maintaining therapeutic response and drug durability during the initial phase of treatment.
Special Instructions
Sample collection should occur ≤3 days prior to receiving the third dose of IFX induction therapy. Precise scheduling and dosage recording are essential for accurate interpretation.
Limitations
The test has been developed as a laboratory-developed test under CLIA guidelines and is not FDA-approved. Therefore, its clinical use should be interpreted with this limitation in mind. It may not detect all possible pharmacokinetic variables and does not provide insights into other non-measured biologics or their interactions.
Methodology
Immunoassay (Proteomic Panel)
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.0 mL
Minimum Volume
Not provided
Container
Serum Separator Tube or Red-Top Tube
Collection Instructions
Collect sample ≤3 days prior to IFX induction dose 3.
Storage Instructions
Ambient or cold pack. Do not freeze.
Causes for Rejection
Unlabeled specimens; incorrect tube type
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
Other tests from different labs that may be relevant